[smartdoctor] Re: Fw: Re: Afera Pfizer
- From: aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>
- To: "smartdoctor@xxxxxxxxxxxxx" <smartdoctor@xxxxxxxxxxxxx>
- Date: Mon, 13 Aug 2012 11:22:58 -0700 (PDT)
Veceras u 20.35 na HRT1 "U krupnom planu": Afera Pfizer, ne bi bilo loše
pogledati!
________________________________
From: Dr. Jadranka Okmazic <okmazic.jadrankaord.opce.medicine@xxxxxxxxxxx>
To: smartdoctor@xxxxxxxxxxxxx
Sent: Friday, August 10, 2012 5:41 PM
Subject: [smartdoctor] Fw: Re: Afera Pfizer
----- Original Message -----
From: aleksandar ljubotina
To: smartdoctor@xxxxxxxxxxxxx
Sent: Friday, August 10, 2012 12:08 PM
Subject: [smartdoctor] Re: Afera Pfizer
Hvala ti Jadranka, problem je što javna gladila ne glade SLOM-ove, nego neke
druge socijalne skupine u RH...ali vrijedi se boriti -
________________________________
From: J Soic <jsoic@xxxxxxxxx>
To: Listaaa <smartdoctor@xxxxxxxxxxxxx>
Sent: Friday, August 10, 2012 11:24 AM
Subject: [smartdoctor] Re: Afera Pfizer
Ovaj bih mail objavila u javnim gladilima u ime svih obiteljskih lijecnika.
Sent from Yahoo! Mail on Android
________________________________
From: aleksandar ljubotina <alexandar_ljubotina@xxxxxxxxx>;
To: smartdoctor@xxxxxxxxxxxxx <smartdoctor@xxxxxxxxxxxxx>;
Subject: [smartdoctor] Re: Afera Pfizer
Sent: Fri, Aug 10, 2012 7:56:42 AM
Dragi svi,
nekako mi se čini da je farmaceutska tvrtka s dva nježna ženska imena u nazivu
nadmašila Pfizer, barem u RH: Forteo, Byetta, Zypadhera...uvjeren sam da ti
lijekovi nisu osvanuli na listi HZZO-a posredovanjem i zaslugom obiteljskih
liječnika.
Molim da uočite da smo napokon izjednačeni s uglednim profesorima iz
različitih odbora za lijekove i predstojnicima klinika,ako već ne po
stručnosti, onda po koruptivnom potencijalu.. Naglasak je na potencijalu, jer
sumnjam da bilo tko od nas ima inozemne bankovne račune u koje redovito
mjesečno kapne koja tisućica eura, i pun salon trofeja s afričkih safarija. Ako
uzmemo da prosječni SLOM propiše lijekova u vrijednosti barem milijun HRK
godišnje, pa još uzmemo u račun od novinara spominjanih 12%, farmaceutske nam
kuće duguju barem 2-3 apartmana na moru ( čak i ako odbijemo kemijske, ručnike,
ruksake i kotizacije za kongrese OM- imamo ih čak četiri godišnje, što jasno
ukazuje da nam je samo od farmaceutskih tvrtki plaćeni nerad na pameti).
Još nešto, gdje su u toj koruptivnoj priči magistre/i farmacije? Novinari ili
misle da one/i ne igraju tu nikakvu ulogu, ili ih drže prvenstveno trgovcima
kojima razni rabati i nagradna putovanja spadaju u opis radnog mjesta.
Pitanje za medije: Ako nas neka generička firma (takve uglavnom surađuju s
OM) plaćanjem nekog od kongresa OM motivira na propisivanje njihovih lijekova
koji su najjeftiniji među paralelama, i na taj način smanjimo HZZ-u troškove za
desetak posto, je li to baš takav sukob interesa zbog kojega smo zaslužili stup
srama?
Mislim da bi u ovom trenutku mi kao obiteljski liječnici trebali odigrati
proaktivan potez prema farmaceustkim tvrtkama, a zašto ne i prema HZZO-u, sa
zahtjevom da većinu stručnih predavanja za obiteljske drže obiteljski
liječnici, uz honorar daleko niži od bolničkih kolega, a razliku bi
farmaceutske kuće mogle transparentno uložiti u fond za opremanje ambulanti.
Time bi javnosti pokazali da nam je temeljni cilj pružanje što kvalitetnije
usluge svojim pacijentima, a jedini način "bogaćenja" bio bi preko DTP
postupaka (delimitiranih) koje bi odrađivali uz pomoć te opreme (koja može
biti i u vlasništvu HZZO-a, da je slučajno ne bi preprodavali na "crnom"
tržištu).
Pozdrav, Saša
________________________________
From: Leonardo Bressan <ordinacija.dr.leonardo.bressan@xxxxxxxxx>
To: smartdoctor@xxxxxxxxxxxxx
Sent: Friday, August 10, 2012 8:48 AM
Subject: [smartdoctor] Afera Pfizer
SEC Charges Pfizer with FCPA Violations
FOR IMMEDIATE RELEASE
2012-152
Washington, D.C., Aug. 7, 2012 – The Securities and Exchange Commission today
charged Pfizer Inc. with violating the Foreign Corrupt Practices Act (FCPA)
when its subsidiaries bribed doctors and other health care professionals
employed by foreign governments in order to win business.
The SEC alleges that employees and agents of Pfizer’s subsidiaries in Bulgaria,
China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia made
improper payments to foreign officials to obtain regulatory and formulary
approvals, sales, and increased prescriptions for the company’s pharmaceutical
products. They tried to conceal the bribery by improperly recording the
transactions in accounting records as legitimate expenses for promotional
activities, marketing, training, travel and entertainment, clinical trials,
freight, conferences, and advertising.
________________________________
Additional Materials
* SEC Complaint Against Pfizer
* SEC Complaint Against Wyeth
* More SEC FCPA Cases
________________________________
The SEC separately charged another pharmaceutical company that Pfizer acquired
a few years ago – Wyeth LLC – with its own FCPA violations. Pfizer and Wyeth
agreed to separate settlements in which they will pay more than $45 million
combined to settle their respective charges. In a parallel action, the
Department of Justice announced that Pfizer H.C.P. Corporation agreed to pay a
$15 million penalty to resolve its investigation of FCPA violations.
“Pfizer subsidiaries in several countries had bribery so entwined in their
sales culture that they offered points and bonus programs to improperly reward
foreign officials who proved to be their best customers,” said Kara Brockmeyer,
Chief of the SEC Enforcement Division’s Foreign Corrupt Practices Act Unit.
“These charges illustrate the pitfalls that exist for companies that fail to
appropriately monitor potential risks in their global operations.”
According to the SEC’s complaint against Pfizer filed in U.S. District Court
for the District of Columbia, the misconduct dates back as far as 2001.
Employees of Pfizer’s subsidiaries authorized and made cash payments and
provided other incentives to bribe government doctors to utilize Pfizer
products. In China, for example, Pfizer employees invited “high-prescribing
doctors” in the Chinese government to club-like meetings that included
extensive recreational and entertainment activities to reward doctors’ past
product sales or prescriptions. Pfizer China also created various “point
programs” under which government doctors could accumulate points based on the
number of Pfizer prescriptions they wrote. The points were redeemed for various
gifts ranging from medical books to cell phones, tea sets, and reading glasses.
In Croatia, Pfizer employees created a “bonus program” for Croatian doctors who
were employed in senior positions in
Croatian government health care institutions. Once a doctor agreed to use
Pfizer products, a percentage of the value purchased by a doctor’s institution
would be funneled back to the doctor in the form of cash, international travel,
or free products.
According to the SEC’s complaint, Pfizer made an initial voluntary disclosure
of misconduct by its subsidiaries to the SEC and Department of Justice in
October 2004, and fully cooperated with SEC investigators. Pfizer took such
extensive remedial actions as undertaking a comprehensive worldwide review of
its compliance program.
The SEC further alleges that Wyeth subsidiaries engaged in FCPA violations
primarily before but also after the company’s acquisition by Pfizer in late
2009. Starting at least in 2005, subsidiaries marketing Wyeth nutritional
products in China, Indonesia, and Pakistan bribed government doctors to
recommend their products to patients by making cash payments or in some cases
providing BlackBerrys and cell phones or travel incentives. They often used
fictitious invoices to conceal the true nature of the payments. In Saudi
Arabia, Wyeth’s subsidiary made an improper cash payment to a customs official
to secure the release of a shipment of promotional items used for marketing
purposes. The promotional items were held in port because Wyeth Saudi Arabia
had failed to secure a required Saudi Arabian Standards Organization
Certificate of Conformity.
Following Pfizer’s acquisition of Wyeth, Pfizer undertook a risk-based FCPA due
diligence review of Wyeth’s global operations and voluntarily reported the
findings to the SEC staff. Pfizer diligently and promptly integrated Wyeth’s
legacy operations into its compliance program and cooperated fully with SEC
investigators.
In settling the SEC’s charges, Wyeth neither admitted nor denied the
allegations. Pfizer consented to the entry of a final judgment ordering it to
pay disgorgement of $16,032,676 in net profits and prejudgment interest of
$10,307,268 for a total of $26,339,944. Wyeth also is required to report to the
SEC on the status of its remediation and implementation of compliance measures
over a two-year period, and is permanently enjoined from further violations of
Sections 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange Act of 1934.
Wyeth consented to the entry of a final judgment ordering it to pay
disgorgement of $17,217,831 in net profits and prejudgment interest of
$1,658,793, for a total of $18,876,624. As a Pfizer subsidiary, the status of
Wyeth’s remediation and implementation of compliance measures will be subsumed
in Pfizer’s two-year self-reporting period. Wyeth also is permanently enjoined
from further violations of Sections 13(b)(2)(A)
and 13(b)(2)(B) of the Exchange Act. The settlements are subject to court
approval.
The SEC’s investigation was conducted by Michael Catoe and Charles Cain of the
Enforcement Division’s FCPA Unit. The SEC acknowledges the assistance of the
U.S. Department of Justice’s Criminal Division’s Fraud Section and the Federal
Bureau of Investigation in this matter.
# # #
http://www.sec.gov/news/press/2012/2012-152.htm __________ NOD32 2604
(20071019) Informacija __________Ova je poruka provjerena NOD32 antivirusnim
sistemom.http://www.nod32.com.hr/
Other related posts:
